Carette 1986.

Study characteristics
Methods	Design: parallel Duration: baseline and post‐intervention Assessment: 9 weeks Country: Canada
Participants	Pain condition: primary fibrositis/fibromyalgia Population: people with fibromyalgia Minimum pain intensity: NR Inclusion criteria Widespread pain lasting > 3 months Local tenderness at 12 out of 14 specified sites Exclusion criteria History of heart conditions Treated with amitriptyline in the previous year Total participants randomised: 70 Age in years (mean): 41 Gender: 54/70 were female Pain duration in months (mean): 84
Interventions	Placebo n = 36 Identical appearance Inert Amitriptyline 10‐50 mg n = 34 TCA Forced titration to fixed doses dependent upon tolerability
Outcomes	Pain intensity AEs Withdrawal
Missing data methods	Completer analysis only
Funding source	Non‐pharmaceutical ‐ Arthritis Grant
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not specified
Allocation concealment (selection bias)	Unclear risk	Allocation procedure not specified
Blinding of participants and personnel (performance bias) All outcomes	High risk	Although the study used double‐blind procedures, the authors noted that 70% of the amitriptyline participants experienced side effects that, in some cases, unblinded participants and research staff.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Self‐reported outcomes from participants who may have been unblinded
Incomplete outcome data (attrition bias) All outcomes	High risk	Completer analysis only Attrition Total: 11/70 (15.7%) Placebo: 4/32 (11.1%) Amitriptyline 10‐50 mg: 7/27 (20.6%)
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias were identified.